Clinical trial
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent…
NCT00046787 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00046787 |
|---|---|
| Title | Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer |
| Official title | Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | SCLC, Carcinoma, Small Cell |
| Intervention type | Drug |
| Interventions | OSI-211 (Liposomal Lurtotecan) |
| Enrollment | 47 |
| Start date | Sep 1, 2002 |
| Completion | Feb 1, 2003 |
| First posted | Oct 4, 2002 |
| Last update posted | Oct 20, 2011 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: